Glucos B. Braun

Glucos B. Braun is a sterile solution for injection containing glucose monohydrate as the sole active ingredient. Formulated as an intravenous carbohydrate source, the product is supplied in a standard concentration (strength not specified) for parenteral use. Marketed in the European Union, it is classified as an excipient/solvent and is available by prescription only. The solution provides readily available energy for patients requiring parenteral nutrition or rapid glucose replacement.

Glucos B. Braun is employed in clinical settings where intravenous carbohydrate delivery is required.

- Parenteral nutrition for patients unable to receive enteral feeding. - Acute treatment of hypoglycemia when oral glucose is not feasible. - Fluid and electrolyte replacement as part of balanced IV therapy. - Energy source during peri‑operative fasting or critical illness. - Support for metabolic demands in burn or trauma patients. - Adjunct in neonatal intensive care for glucose maintenance.

When administered intravenously, Glucos B. Braun may be associated with a range of observed effects, most of which are related to the infusion itself or to rapid changes in blood glucose.

Common: - Transient hyperglycemia or hypoglycemia depending on infusion rate. - Local irritation or pain at the injection site. - Mild electrolyte shifts, particularly sodium or potassium. - Nausea or feeling of fullness during rapid infusion.

Serious: - Severe hyperglycemia leading to osmotic diuresis. - Hypoglycemic coma if glucose falls abruptly after infusion stops. - Fluid overload causing pulmonary edema. - Allergic reaction such as urticaria or anaphylaxis.

Clinicians should observe specific precautions when prescribing Glucos B. Braun to minimize risks and ensure appropriate therapeutic outcomes.

- Verify patient’s baseline blood glucose and adjust infusion rate accordingly. - Assess fluid balance and cardiac function to avoid overload. - Use aseptic technique to prevent contamination of the IV solution. - Monitor electrolytes, especially sodium, potassium, and phosphate, during prolonged therapy. - Consider reduced concentrations in neonates and infants. - Avoid use in patients with known hypersensitivity to glucose preparations. - Document infusion parameters and patient response in the medical record.

Glucos B. Braun can interact with other intravenous agents or systemic medications, influencing glucose homeostasis or fluid status.

Avoid: - Concurrent high‑dose insulin infusions without close glucose monitoring. - Co‑administration with other hypertonic dextrose solutions that may cause severe hyperglycemia. - Use with potassium‑rich solutions in patients at risk of hyperkalemia without electrolyte checks.

Use with caution: - Simultaneous administration of diuretics that may alter fluid balance. - Combination with corticosteroids that increase glucose production. - Co‑infusion with calcium‑containing solutions, which may precipitate if mixed improperly.